Been digging into some interesting plays in the psychedelic therapeutics space lately, and honestly there are a few names worth looking at even after the initial hype cycle died down.

So here's the thing - while everyone was focused on cannabis becoming mainstream, there's this whole other wave of alternative medicine trying to break through. Psilocybin, ketamine, LSD... these compounds are getting serious clinical attention now. The research is actually compelling. Multiple studies showing real efficacy for treatment-resistant depression when dosed properly.

The companies that went public around this got absolutely hammered after the initial run. Classic biotech pattern - excitement spike followed by brutal selloff. But that created some opportunities if you're patient enough to wait for catalysts.

Let me break down the main psychedelic stocks worth watching:

First up is Atai Life Sciences. This is the broad-based play - they're running multiple programs with ketamine, DMT, psilocybin derivatives. Their most advanced candidate COMP360 hit Phase 3 trials. Yeah, it's capital intensive and puts pressure on the balance sheet, but that diversification actually increases the odds of something breaking through. The stock got absolutely destroyed - trading at like a 93% discount from IPO price at the time. Any positive trial data could move this thing hard.

Then there's Compass Pathways. These guys are basically all-in on psilocybin therapeutics through COMP360. It's a more focused bet than Atai. Their Phase 2b data was actually pretty solid - 20% of treatment-resistant depression patients showed sustained improvement by week 12. Remember, these are people who didn't respond to traditional SSRIs. That's a meaningful result in this space.

Cybin is the third one. They're developing multiple psilocybin-based therapies and got FDA breakthrough therapy designation for treating major depressive disorder. The stock trades super cheap, which attracts certain investors, but it's still early stage with no revenue. Just losses so far. That's the trade-off with early biotech plays.

The real catalyst here is FDA approval. Once one of these psychedelic stocks clears that hurdle, the narrative shifts completely. We're probably not that far away. The clinical evidence keeps building, and the regulatory environment is thawing. Worth keeping on your radar if you're willing to stomach the volatility.